Takeda's arcotatug tavatecan meets dual primary endpoints in Phase 3 gastric cancer study
What's the deal? TakedaDealroom has a profile for this one. Try Dealroom → has announced that its experimental cancer therapy arcotatug tavatecan (TAK-921) met both primary endpoints in the Phase 3 G-HOPE-001 trial in advanced gastric (stomach) cancer. The results were presented as a late-breaking oral presentation at the ESMO 2026 congress.
The results: The study enrolled 464 patients in Japan and China whose stomach tumours carry a specific protein marker called CLDN18.2 on their surface, and who had already progressed on two to four prior treatment regimens. Arcotatug tavatecan significantly improved both overall survival (OS) and progression-free survival (PFS) compared with physician's choice chemotherapy (irinotecan, paclitaxel or trifluridine/tipiracil). In the second pre-specified interim analysis, with a data cut-off of 3 September 2026, median overall survival was 10.2 months with arcotatug tavatecan versus 6.9 months with chemotherapy (hazard ratio 0.57, p<0.0001).
Why it matters: Arcotatug tavatecan is an antibody-drug conjugate — a type of precision therapy that binds to a marker found on tumour cells and delivers a cell-killing drug directly to them, sparing healthy tissue. Advanced gastric cancer patients who have exhausted several prior lines of treatment currently have limited options, so a statistically significant survival benefit in this setting is a meaningful signal. Takeda will discuss next steps, including regulatory submission, with health authorities.
Read more: Takeda, 23 October 2026